Our series of annual reports on Measuring the return from pharmaceutical innovation has provided insights into the state of biopharma R&D since 2010. We have expanded the analysis over time and our data set now covers the top 20 pharma companies by R&D spend. This year’s analysis demonstrates the step change we anticipated, in our 2021 report Nurturing growth, is yet to be realised.
top of page
bottom of page